Angiotensin II (Ang II) has historically been considered the main effector of the renin-angiotensin system and nowadays drugs interfering with the renin angiotensin system, as ACE-inhibitors or AT1 blockers, represent the therapeutic cornerstone to treat hypertension and to counteract cardiovascular and renal diseases [1,2]. This evidence concerns the gene AGT and kidney disorder.